###begin article-title 0
Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
###end article-title 0
###begin p 1
Conceived and designed the experiments: BSJ SS. Performed the experiments: BSJ VJ NMK. Analyzed the data: BSJ JEA JC KPH SS. Contributed reagents/materials/analysis tools: YL DD KPH. Wrote the paper: BSJ SS.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Oncogenic RAS is a highly validated cancer target. Attempts at targeting RAS directly have so far not succeeded in the clinic. Understanding downstream RAS-effectors that mediate oncogenesis in a RAS mutant setting will help tailor treatments that use RAS-effector inhibitors either alone or in combination to target RAS-driven tumors.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 181 188 181 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 260 264 260 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G13D</sup>
###xml 416 423 416 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 460 464 460 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61L</sup>
###xml 472 476 472 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61K</sup>
###xml 189 194 <span type="species:ncbi:10090">mouse</span>
In this study, we have investigated the sufficiency of targeting RAS-effectors, RAF, MEK and PI3-Kinase either alone or in combination in RAS mutant lines, using an inducible shRNA in vivo mouse model system. We find that in colon cancer cells harboring a KRASG13D mutant allele, knocking down KRAS alone or the RAFs in combination or the RAF effectors, MEK1 and MEK2, together is effective in delaying tumor growth in vivo. In melanoma cells harboring an NRASQ61L or NRASQ61K mutant allele, we find that targeting NRAS alone or both BRAF and CRAF in combination or both BRAF and PIK3CA together showed efficacy.
###end p 5
###begin title 6
Conclusion/Significance
###end title 6
###begin p 7
Our data indicates that targeting oncogenic NRAS-driven melanomas require decrease in both pERK and pAKT downstream of RAS-effectors for efficacy. This can be achieved by either targeting both BRAF and CRAF or BRAF and PIK3CA simultaneously in NRAS mutant tumor cells.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 129 132 129 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Schubbert1">[1]</xref>
###xml 133 136 133 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Kratz1">[3]</xref>
###xml 303 306 303 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-DiazFlores1">[2]</xref>
###xml 115 120 <span type="species:ncbi:9606">human</span>
Oncogenic mutations in the RAS family of small GTPases, KRAS, HRAS and NRAS, occur in approximately a third of all human cancers [1]-[3]. This makes RAS a prime target for drug development. However, efforts at developing therapeutics that target mutant RAS directly so far have not been very successful [2].
###end p 9
###begin p 10
###xml 420 423 414 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Repasky1">[4]</xref>
###xml 425 428 419 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Balmanno1">[5]</xref>
Understanding the signaling pathways engaged by oncogenic RAS in promoting malignant transformation is fundamental to identifying and targeting components downstream of RAS. Several studies have helped identify major RAS effector molecules which include the Raf kinases, class I phosphoinositide 3-kinases (PI3K), Ral guanine nucleotide exchange factors (Ral-GEFs), Rac exchange factor Tiam1, and phospholipase Cepsilon [4], [5].
###end p 10
###begin p 11
The RAF kinases, members of the three-component MAP Kinase cascade, once activated by GTP-bound RAS, phosphorylate and activate dual-specificity kinases MEK1 and MEK2, which in-turn activate MAP Kinases ERK1 and ERK2. Active ERK1/2 then translocates to the nucleus to exert their biological effects. PIK3CA, a PI3K family member stimulated through RAS activation, phosphorylates its lipid substrate phosphatidylinositol (4,5) bisphosphate (PIP2) to produce phosphatidylinositol (3,4,5) triphosphate (PIP3). This phosphorylated lipid PIP3 is an important cellular second messenger that promotes the activation of AKT (AKT1, AKT2 and AKT3) leading to cell survival.
###end p 11
###begin p 12
###xml 120 123 120 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Bader1">[6]</xref>
###xml 125 128 125 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Dhomen1">[7]</xref>
###xml 253 256 253 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Bader1">[6]</xref>
###xml 258 261 258 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Dhomen1">[7]</xref>
###xml 395 398 395 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Rossi1">[8]</xref>
###xml 532 535 532 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Samuels1">[9]</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Zhao1">[11]</xref>
###xml 846 849 846 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Dhomen1">[7]</xref>
###xml 851 855 851 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Ollikainen1">[12]</xref>
###xml 857 861 857 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Velho1">[13]</xref>
###xml 955 959 955 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Ollikainen1">[12]</xref>
###xml 961 965 961 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Velho1">[13]</xref>
###xml 1304 1308 1304 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Gupta1">[14]</xref>
###xml 1456 1460 1456 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Chudnovsky1">[15]</xref>
###xml 1714 1718 1714 1718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Lim1">[16]</xref>
###xml 106 111 <span type="species:ncbi:9606">human</span>
###xml 1168 1173 <span type="species:ncbi:10090">mouse</span>
###xml 1298 1303 <span type="species:ncbi:10090">mouse</span>
###xml 1335 1340 <span type="species:ncbi:9606">human</span>
###xml 1352 1357 <span type="species:ncbi:10090">mouse</span>
Besides mutations in RAS, activating somatic mutations in its effectors PIK3CA and BRAF, occur in various human cancers [6], [7]. While PIK3CA mutations are more prevalent in colon and breast cancer, BRAF mutation occurs at a high frequency in melanoma [6], [7]. Additionally, loss-of-function of the PTEN tumor suppressor gene, which leads to activation of PI3-kinase, is widespread in cancers [8]. Functional studies that dissect PIK3CA and BRAF somatic mutations have established the oncogenic nature of these RAS effector genes [9]-[11]. Further, these studies show that each effector arm on its own when activated is sufficient to promote tumor formation, especially, in tumor types where they are commonly mutated. Interestingly, BRAF mutations are mutually exclusive with NRAS mutations in melanoma and KRAS mutations in colorectal cancer [7], [12], [13]. In contrast, mutations in PIK3CA are not mutually exclusive with KRAS in colorectal cancers [12], [13]. The patterns of mutational co-occurrence, suggests that each RAS-effector is differentially employed in promoting tumor initiation in a tumor tissue specific manner. A recent study using an engineered mouse model showed the importance of intact signaling via the PI3K RAS-effector arm for initiation of lung tumors in a RAS-mutant mouse [14]. Similarly, in engineered human skin graft mouse models, the PI3K effector arm was found to be equivalent to RAS in inducing melanocytic neoplasia [15]. Another study, using engineered cell lines that express various RAS-mutants that can preferentially engage either RAF, PI3K or RalGEF showed that while all three were important for tumor initiation, the PI3K pathway was essential for tumor maintenance [16].
###end p 12
###begin p 13
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Schreck1">[17]</xref>
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Haluska1">[18]</xref>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Haluska1">[18]</xref>
###xml 296 300 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Roberts1">[21]</xref>
###xml 502 506 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Bedogni1">[22]</xref>
###xml 507 511 507 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Engelman1">[25]</xref>
###xml 611 615 611 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Campbell1">[26]</xref>
###xml 726 730 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Dumaz1">[27]</xref>
###xml 732 736 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Smalley1">[28]</xref>
###xml 918 925 918 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 270 275 <span type="species:ncbi:9606">human</span>
###xml 784 789 <span type="species:ncbi:10090">mouse</span>
Pharmacological inhibitors that target RAS effectors, RAF and PI3Ks, are in various stages of clinical trials [17], [18]. Small molecule inhibitors that target downstream components of these effectors, MEK1/2 and AKT1/2/3 have been developed and are undergoing tests in human trials as well [18]-[21]. Using pharmacological inhibitors of PI3K and RAF effectors, various studies have demonstrated the importance of either the PI3K or RAF arms or the requirement for targeting both in RAS mutated tumors [22]-[25]. In pancreatic epithelial cells, KRAS mediated transformation requires both RAF and PI3K signaling [26]. In NRAS mutated melanoma cells, CRAF was demonstrated to be the major RAS effector for signaling through ERK [27], [28]. These along with the studies using engineered mouse models and cell lines have yielded results that are often contradictory and confounding, underscoring the importance of further in vivo studies that address the relevance of these components in initiation, maintenance and progression of cancers.
###end p 13
###begin p 14
###xml 50 54 50 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Gray1">[29]</xref>
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Hoeflich1">[30]</xref>
###xml 250 257 250 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 268 273 <span type="species:ncbi:10090">mouse</span>
Using a recently described inducible shRNA system [29], we have previously shown that signaling via oncogenic BRAF is essential for tumor initiation and maintenance in melanoma models [30]. In this study, we have used this inducible shRNA system and in vivo xenograft mouse model to demonstrate the effectiveness of targeting downstream RAS-effectors either alone or in combination as strategies for treatment of RAS driven cancers.
###end p 14
###begin title 15
Results
###end title 15
###begin title 16
Oncogenic RAS-mutant cancer cells require RAS for proliferation, anchorage independent growth and tumor formation
###end title 16
###begin p 17
###xml 47 51 47 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G13D</sup>
###xml 119 123 119 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61L</sup>
###xml 405 413 405 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005717.s003">Table S1</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Gray1">[29]</xref>
###xml 872 881 872 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g001">Figure 1A</xref>
###xml 1929 1938 1929 1938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g001">Figure 1B</xref>
###xml 2189 2198 2189 2198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g001">Figure 1B</xref>
###xml 2361 2377 2361 2377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g001">Figure 1C and 1D</xref>
###xml 2628 2635 2628 2635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2735 2756 2735 2756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">materials and methods</xref>
###xml 2770 2785 2770 2785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g001">Figure 1E and G</xref>
###xml 2874 2881 2874 2881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2922 2931 2922 2931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g001">Figure 1F</xref>
###xml 2953 2962 2953 2962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g001">Figure 1H</xref>
###xml 3089 3096 3089 3096 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
HCT116, a colon cancer line that harbors a KRASG13D mutation and IPC298, a cutaneous melanoma cell line bearing an NRASQ61L mutation, were chosen for this study since KRAS in colorectal cancer and NRAS in melanoma is the most frequently mutated RAS gene in these tumor types. The colon cancer cell line HCT116, in addition to KRAS mutation, also harbors an activating mutation in the RAS effector PIK3CA (Table S1). In order to understand the relevance of oncogenic RAS and its dependence on its major downstream effectors, RAF and PI3K, we used a previously described doxycycline (dox)-inducible shRNA system [29] to study the effects of RAS knockdown on cellular proliferation and tumor growth. We generated pools of cells expressing shRNAs that target RAS in a dox-inducible fashion. Upon dox treatment RAS, KRAS in HCT116 and NRAS in IPC298, was effectively silenced (Figure 1A). Consistent with the loss of signaling from RAS, the levels of phospho ERK decreased in both the RAS mutant lines, relative to the total ERK in these lines. In addition to loss of phosphoERK levels, RAS knock-down in both IPC298 and HCT116 cells led to a decrease in the phospho AKT levels. Phospho AKT levels were reduced in KRAS knock-down HCT116 cells despite the presence of PIK3CA mutation in this line. In both lines the control luciferase shRNA-expressing cells upon dox induction did not show any changes in either the phospho or the total ERK levels. Similarly, the phospho and total AKT levels were not modulated significantly in these cells following dox addition. To determine the requirement of RAS in these RAS-mutant cancer lines for cellular proliferation, we studied these lines for growth following induction of shRNAs that target NRAS or KRAS. We found that, consistent with the loss of downstream signaling following abrogation of KRAS in HCT116 and NRAS in IPC298, cell proliferation was reduced by 40% and 60% respectively (Figure 1B). We found a similar trend in proliferation with a second shRNA that targeted KRAS or NRAS in these lines (data not shown). Compared to the RAS knock-down lines, the luciferase control lines showed no effect on proliferation following dox induction (Figure 1B). In addition to the effect seen on proliferation, RAS knock down led to a 5-6-fold decrease in anchorage-independent growth in both the HCT116 and IPC298 cells (Figure 1C and 1D). These results demonstrate that both lines were dependent on RAS, KRAS in HCT116 and NRAS in IPC298, for their proliferation and anchorage-independent growth. We next tested the relevance of oncogenic RAS in the RAS-mutant lines for tumor formation in vivo by establishing s.c. tumors and inducing the targeting shRNA in established tumors as described in materials and methods. As shown in Figure 1E and G, the control luciferase oligo induction had no effect on the growth of HCT116 or IPC298 in vivo. However, knocking down KRAS in HCT116 (Figure 1F) and NRAS in IPC298 (Figure 1H) led to a significant delay in tumor growth, indicating the requirement of KRAS in HCT116 and NRAS in IPC298 for tumor growth in vivo.
###end p 17
###begin title 18
###xml 104 111 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
KRAS or NRAS, in RAS mutant lines, is required for cell proliferation, anchorage independent growth and in vivo tumor growth and progression.
###end title 18
###begin p 19
###xml 675 682 672 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 838 842 <span type="species:ncbi:10090">mice</span>
(A) Western blot analysis of KRAS and NRAS knock-down in HCT116 and IPC298 cells, respectively. Lysates from cells expressing KRAS, NRAS or control luciferase (shLUC) shRNA, prepared 72 h post treatment with dox, were analyzed, as indicated, by immunoblotting. beta-actin levels in the blot serves as a loading control. (B) Proliferation of KRAS or NRAS shRNA expressing cells after 4 days post dox treatment. (C-D) KRAS and NRAS shRNA induction, in HCT116 and ICP298 respectively leads to reduced anchorage independent growth of these cells. Representative images (C) and colony count (D) are shown. (E-H) RAS knock-down, KRAS in HCT116 (F), and, NRAS in IPC298 (H), delays in vivo tumor growth. Induction of LUC shRNA in control cells (E, G) had no effect on tumor growth. Each data point is the mean+/-SEM tumor volume derived from 10 mice. Dotted line in (E-H) represents data from dox treated animals.
###end p 19
###begin title 20
Differential effects of targeting downstream RAS-effectors on tumor growth in RAS mutant cancer cells
###end title 20
###begin p 21
###xml 582 590 582 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 609 616 609 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
RAS predominantly engages the RAF pathway and the PI3K pathway as major downstream effectors in various cancers. We sought to examine the contribution of these two arms in tumor growth and progression. In addition to elucidating the role of these two RAS-effector arms in cancer, this knowledge should provide insight into targeting RAS-driven tumors. We therefore generated pools of either HCT116 or IPC298 cells harboring inducible shRNAs that target, BRAF, CRAF, MEK1, MEK2 and PIK3CA either singly or in various combinations within the same line. We then tested these lines for in vitro proliferation and in vivo tumor growth.
###end p 21
###begin p 22
###xml 170 179 170 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g002">Figure 2A</xref>
###xml 534 543 534 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g002">Figure 2B</xref>
###xml 555 562 555 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 687 696 687 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g002">Figure 2C</xref>
###xml 861 869 861 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 874 881 874 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 883 899 883 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g001">Figure 1B and 1F</xref>
###xml 1101 1110 1101 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g002">Figure 2D</xref>
###xml 1783 1792 1783 1792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3A</xref>
###xml 1968 1976 1968 1976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2062 2071 2062 2071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3A</xref>
###xml 2268 2277 2244 2253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3C</xref>
###xml 2281 2287 2257 2263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n vivo</italic>
###xml 2402 2411 2378 2387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3E</xref>
###xml 2528 2537 2504 2513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3D</xref>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 949 958 <span type="species:ncbi:10090">nude mice</span>
HCT116-BRAF knockdown line, upon dox treatment showed reduction in BRAF protein levels and a concomitant decrease in phospho ERK levels relative to the total ERK levels (Figure 2A). Similarly, HCT116-PIK3CA knockdown lines when treated with dox showed a reduction in the levels of PIK3CA and a decrease in phospho AKT compared to the control un-induced cells. In proliferation studies, both the dox treated PIK3CA knockdown and BRAF knockdown HCT116 lines showed a 20-25% reduction in proliferation compared to non-dox treated cells (Figure 2B). However, in vivo, mice bearing tumors derived from PIK3CA knock-down HCT116-cells, showed no effect on tumor growth following dox treatment (Figure 2C). These results are consistent with the fact that the mutant PIK3CA in HCT116 did not functionally substitute for KRAS in experiments where KRAS was silenced, both in vitro and in vivo (Figure 1B and 1F). In contrast to knock-down of PIK3CA in HCT116, nude mice bearing subcutaneous tumors resulting from injected HCT116 BRAF-inducible shRNAs cells, when treated with dox showed a delay in tumor growth (Figure 2D). The delay was not statistically significant, in part due to the outlier tumor volumes observed towards the end of this study. However, this could also be in part due to the fact that the oncogenic RAS could engage other RAF family members like CRAF and continue to promote tumor growth and survival. To fully evaluate the contributions of the RAF arm that could result from engagement of other RAFs, we generated HCT116 inducible shRNA knock-down lines where we conditionally silenced CRAF or both CRAF and BRAF together. As expected, knock-down of BRAF and CRAF together decreased pMEK level completely, while knock-down of CRAF alone showed some residual pMEK levels (Figure 3A). Consistent with this finding, the BRAF/CRAF double knock-down line showed a decrease in pERK levels while the CRAF knock-down alone did not substantially affect pERK levels in vitro. However, knock-down of either CRAF or BRAF and CRAF together decreased pAKT levels (Figure 3A). In proliferation studies, CRAF knock-down lines showed a approximately25% decrease in proliferation, while the combined CRAF and BRAF knock down had approximately40% reduction in proliferation (Figure 3C). In vivo, combined CRAF and BRAF knock-down showed a significant delay in tumor growth compared to the un-induced control (Figure 3E). Although not as significant as the dual RAF knock-down, CRAF knock-down alone significantly delayed tumor growth (Figure 3D). These results suggest that KRAS in HCT116 cells engages both CRAF and BRAF for promoting tumor growth with CRAF being the dominant effector arm.
###end p 22
###begin title 23
###xml 44 48 44 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G13D</sup>
Effect of BRAF and PIK3CA knock-down on KRASG13D mutant HCT116 cell growth.
###end title 23
###begin p 24
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
(A) Western blot analysis of PIK3CA or BRAF knock-down in HCT116 at 72 h post dox induction of relevant shRNAs. The effect of knock-down on the phosphorylation status of relevant downstream targets is shown. (B) Proliferation of BRAF and PIK3CA shRNA expressing cells 4 days post dox treatment. (C) shRNA targeting PIK3CA when induced in mice bearing HCT116 tumors did not delay tumor growth. (D) BRAF knock-down in HCT116 derived tumors shows a trend towards delayed tumor growth. Each data point is the mean+/-SEM tumor volume derived from 10 mice. Dotted line in (C, D) represents data from dox treated animals.
###end p 24
###begin title 25
###xml 56 60 56 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G13D</sup>
###xml 81 88 81 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
RAF or MEK1-MEK2 double knock-down delays growth of KRASG13D mutant HCT116 cells in vivo.
###end title 25
###begin p 26
###xml 473 480 473 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 565 569 <span type="species:ncbi:10090">mice</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
(A-B) Western blot analysis of CRAF or CRAF and BRAF or MEK1 and MEK2 knock-down in HCT116 at 72 h post dox induction of relevant shRNAs. The effect of knock-down on the phosphorylation status of relevant downstream target is shown. (C) Proliferation of CRAF, CRAF and BRAF, MEK1, MEK2 and double MEK1+2 shRNA expressing cells 4 days post dox treatment. (D-G) shRNA targeting CRAF (D), CRAF and BRAF (E) and MEK1 and MEK2 double knock-down (G) in KRAS-mutant HCT116 tumors in vivo delayed tumor growth. shRNA targeting MEK1 or MEK2 individually (F) when induced in mice bearing HCT116 tumors did not delay tumor growth. Each data point is the mean+/-SEM tumor volume of 10 mice. Dotted line in (D-F) represents data from dox treated animals.
###end p 26
###begin p 27
###xml 530 539 530 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3B</xref>
###xml 716 725 716 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3B</xref>
###xml 814 823 814 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3B</xref>
###xml 848 856 848 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1119 1128 1083 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3C</xref>
###xml 1314 1321 1278 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1449 1458 1413 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3G</xref>
###xml 1502 1511 1466 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g003">Figure 3F</xref>
###xml 1656 1665 1620 1629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005717.s001">Figure S1</xref>
###xml 1342 1351 <span type="species:ncbi:10090">nude mice</span>
Given that several Mek inhibitors are in development in the clinic we sought to test if targeting the RAF effectors MEK1 or MEK2 either alone or together in the same pool of cells would be as effective as targeting the RAFs. We therefore generated HCT116 cells that inducibly express shRNAs targeting MEK1 or MEK2 or both. In these lines upon dox addition, MEK1 in the MEK1-knock-down line, MEK2 in the MEK2-knock-down line, and both MEK1 and MEK2 in the double knock-down line were decreased, compared to the un-induced control (Figure 3B). While the MEK1 or MEK2 knock-down alone did not show a substantial decrease in phospho ERK levels, the double knock-down showed a significant decrease in phopsho ERK levels (Figure 3B). However, knock-down of MEK either alone or in combination does not affect pAKT level (Figure 3B). We tested these lines in vitro for their ability to proliferate in the presence or absence of dox and found that the MEK1, MEK2 and MEK1+2 double lines showed approximately15%, approximately20% and approximately30% reduction in proliferation respectively, compared to untreated control cells (Figure 3C). This suggests that loss of each isoform of MEK has an effect on its own, while the combined knock-down has the most effect on proliferation. We tested the MEK-knock-down HCT116 lines in vivo for tumor growth in nude mice and found that silencing both MEK1 and MEK2 together led to a significant delay in tumor growth (Figure 3G), compared to targeting them individually (Figure 3F). To confirm this further we tested a pharmacological inhibitor of MEK on HCT116 cells and found that it is effective in delaying tumor growth (Figure S1). These results suggest that in the KRAS mutant HCT116 colon cancer cells, the RAF/MEK/ERK effector arm is necessary for cellular proliferation and tumor growth, despite the presence of activating mutation in PIK3CA.
###end p 27
###begin p 28
###xml 235 242 235 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 432 441 432 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4A</xref>
###xml 444 452 444 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 604 613 592 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4C</xref>
###xml 625 632 613 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 734 743 722 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4D</xref>
###xml 1325 1334 1313 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4A</xref>
###xml 1385 1393 1373 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1603 1612 1567 1576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4C</xref>
###xml 1769 1778 1733 1742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4E</xref>
###xml 1916 1925 1880 1889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4F</xref>
###xml 2236 2245 2200 2209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4A</xref>
###xml 1794 1798 <span type="species:ncbi:10090">mice</span>
We extended these studies to the NRAS mutant melanoma IPC298 cells. Given that BRAF is more commonly mutated in melanomas, we hypothesized that targeting the BRAF effector arm alone would be sufficient to affect cell proliferation and in vivo tumor growth. To test this, we generated a stable pool of IPC298 cells harboring an inducible BRAF shRNA. Upon BRAF shRNA induction, we observed a significant decrease in the BRAF protein (Figure 4A). In vitro the BRAF-shRNA expressing IPC298 cells showed a approximately20% decrease in proliferation upon dox treatment relative to the uninduced control cells (Figure 4C). However, in vivo, we found that BRAF silencing did not show a statistically significant delay in IPC298 tumor growth (Figure 4D). This is contrary to our initial hypothesis about BRAF playing a dominant role in tumor cell signaling in melanomas bearing an NRAS mutation. The lack of efficacy in IPC298 cells following BRAF knock-down could be the result of mutant RAS engaging other RAF family member like CRAF. To address this, we generated and tested IPC298 pools that inducibly expressed shRNAs targeting CRAF alone or BRAF and CRAF in combination. Upon induction of corresponding shRNA in these cells, CRAF or BRAF and CRAF proteins were completely depleted leading to a decrease in pMEK and pERK levels (Figure 4A). As with BRAF, knock-down of CRAF also decreased in vitro cell proliferation by approximately20%. We found double knock-down of both BRAF and CRAF to be far more effective leading to a approximately50% reduction in cell proliferation compared to the uninduced cells (Figure 4C). Similar to the effects observed with BRAF knock-down, silencing CRAF alone did not show a statistically significant delay in IPC298 tumor growth in vivo (Figure 4E). In contrast, mice bearing IPC298 co-expressing BRAF and CRAF shRNA showed complete inhibition of tumor growth following dox induction (Figure 4F). These data indicate that the NRAS mutant IPC298 melanoma line engages both the BRAF and CRAF effector arms for survival and proliferation and that targeting both BRAF and CRAF is important for efficacy. Further, both pERK and pAKT levels are decreased only when both BRAF and CRAF are knocked down together (Figure 4A), suggesting that signaling from both the RAF and PI3K effectors need to be inhibited for efficacy.
###end p 28
###begin title 29
###xml 49 53 49 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61L</sup>
###xml 83 90 83 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
BRAF/CRAF double-knock-down delays growth of NRASQ61L-mutant IPC298 melanoma cells in vivo.
###end title 29
###begin p 30
###xml 563 567 <span type="species:ncbi:10090">mice</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
(A-B) Western blot analysis showing BRAF, CRAF, BRAF+CRAF, MEK1, MEK2, and double MEK1/2 knock-down in IPC298 at 72 h after dox induction of shRNAs. The effect of knock-down on the phosphorylation status of relevant downstream targets is shown. (C) Effect of expressing BRAF, CRAF, BRAF+CRAF, MEK1, MEK2 and double MEK1+2 shRNAs on proliferation of IPC298 cells 4 days following dox treatment. (D-G) While shRNA targeting BRAF+CRAF (F) together delayed tumor growth, shRNA targeting BRAF (D), CRAF (E), MEK1, or MEK2 or MEK1 and MEK2 together (G) when induced in mice bearing IPC298 derived tumors did not delay tumor growth. Each data point is the mean+/-SEM tumor volume of 10 mice. Dotted line in (D-G) represents data from dox treated animals.
###end p 30
###begin p 31
###xml 423 432 423 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4B</xref>
###xml 523 532 523 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4B</xref>
###xml 581 589 581 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 694 703 694 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4B</xref>
###xml 848 857 848 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4G</xref>
###xml 1147 1156 1147 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4B</xref>
###xml 1344 1353 1344 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g004">Figure 4A</xref>
Since, both BRAF and CRAF signal through their effectors MEK1 and MEK2, we sought to understand the effect of targeting MEKs in IPC298 cells. We generated and tested IPC298 pools that inducibly expressed shRNAs that target RAF-effectors MEK1 or MEK2 or both MEK1 and MEK2 together in the same cells. The targeted knock-down of MEK1 or MEK2 alone or a combined MEK1 and MEK2 knock-down reduced the levels of these proteins (Figure 4B). The pERK levels were also decreased in these cells compared to control untreated cells (Figure 4B). In all the MEK-shRNA containing IPC298 lines, in vitro we did not observe a significant difference in proliferation between the control and dox-treated cells (Figure 4B). Similarly, silencing MEK1 or MEK 2 alone or in combination, did not show a significant delay in tumor growth relative to the control animals (Figure 4G). This result was unexpected given that CRAF and BRAF targeting was effective, suggesting potential differential survival and proliferation signaling outputs resulting from inhibition of different nodes along the RAS/RAF pathway. Consistent with this, we find pAKT levels to be unchanged (Figure 4B) in the MEK1/2 double knock-down line, although pERK was decreased. This is in contrast to decreases in both the pAKT and pERK levels observed with the BRAF/CRAF double knock-down lines (Figure 4A). Further, this is a likely reason for the lack of efficacy observed in the combined MEK1/2 knock-down as compared to BRAF/CRAF double knock-down. Although the exact cross talk and feedback mechanism leading to the differential modulation of pAKT and pERK in response to knock-down of the various RAF and RAF-effectors is not obvious, this data indicates the requirement for targeting signaling from both ERK and AKT effectors in NRAS mutant lines.
###end p 31
###begin title 32
Combined targeting of RAF and PI3K, RAS-effector arms effectively reduces tumor growth in NRAS mutant tumors
###end title 32
###begin p 33
Given the observed requirement for decrease in both pERK and pAKT downstream of mutant NRAS and the intense efforts to develop inhibitors targeting BRAF, MEK1/2 and PI3K in progress, we sought to understand if combined knock-down of RAF or MEK with PI3K would be an effective strategy for treatment of NRAS mutant melanomas.
###end p 33
###begin p 34
###xml 115 124 115 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g005">Figure 5A</xref>
###xml 175 184 175 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g005">Figure 5A</xref>
###xml 318 327 318 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g005">Figure 5B</xref>
###xml 330 337 330 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 460 469 460 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g005">Figure 5C</xref>
Induction of shRNA targeting PIK3CA alone reduced the levels of PIK3CA, leading to a reduction in the pAKT levels (Figure 5A). However, this did not decrease the pERK levels (Figure 5A). The PIK3CA shRNA line did not show any significant decrease in proliferation following dox treatment, compared to untreated cells (Figure 5B). In vivo, induction of PIK3CA targeting shRNA, did not delay IPC298 tumor growth, compared to animals that were placed on sucrose (Figure 5C). This suggested that targeting the PIK3CA effector arm alone was not sufficient to prevent tumor growth in the NRAS mutant line.
###end p 34
###begin title 35
###xml 60 64 60 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61L</sup>
###xml 113 120 113 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Combined targeting of PIK3CA+BRAF, and PIK3CA+MEK1/2 in NRASQ61L-mutant IPC298 melanoma cell delays tumor growth in vivo.
###end title 35
###begin p 36
###xml 367 374 367 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 574 581 574 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
###xml 636 640 <span type="species:ncbi:10090">mice</span>
(A) Immuno blot analysis of PIK3CA, PIK3CA+BRAF, and PIK3CA+MEK1/2 knock-down in IPC298 cells affects phosphorylation of downstream targets. (B) Proliferation of IPC298 cells expressing shRNAs targeting PIK3CA alone or PIK3CA and BRAF together or PIK3CA together with MEK1/2 4 days after dox treatment. (C) shRNA targeting PIK3CA in IPC298 did not delay tumor growth in vivo, following induction of PIK3CA targeting shRNA. (D-E) Combined induction of BRAF and PIK3CA shRNA together or MEK1 and 2 together with PIK3CA in mice bearing IPC298 derived tumors delay tumor growth in vivo. Each data point is the mean+/-SEM tumor volume of 10 mice. Dotted line in (C-E) represents data from dox treated animals.
###end p 36
###begin p 37
###xml 466 475 466 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g005">Figure 5A</xref>
###xml 1030 1039 1018 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g005">Figure 5B</xref>
###xml 1069 1076 1057 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1321 1337 1309 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g005">Figure 5D and 5E</xref>
To test the possibility that the combined targeting of RAF and PI3K effector arms would be effective in the NRAS mutant background, we generated IPC298 pools that inducibly expressed shRNAs that target either PIK3CA and BRAF together or PIK3CA along with both the RAF-effectors, MEK1 and 2. These cells were characterized for effective knock-down of BRAF, MEKs and PIK3CA. As expected, upon dox treatment the cells showed reduced BRAF, PIK3CA or MEK1 and 2 protein (Figure 5A). Consistent with this, pERK and pAKT levels were diminished, relative to the total amount of ERK and AKT respectively. It is interesting to note that while BRAF or PIK3CA knock-down alone did not affect pERK levels significantly, the combined knock-down of BRAF and PIK3CA led to significant decrease in pERK and pAKT. We studied these cells in proliferation assays and found that there was a approximately25-30% decrease in proliferation when both BRAF and PIK3CA or the RAF-effectors MEK1, 2 and PIK3CA together were knocked down in the IPC298 cells (Figure 5B). We also tested these lines in vivo to see if targeting both BRAF and PIK3CA or both MEK1+2 and PIK3CA will lead to delayed tumor growth. Targeting both the RAS-effector arms, either by combined BRAF and PIK3CA or MEK1+2 and PIK3CA together, effectively delayed the tumor growth (Figure 5D and 5E) confirming the importance of both the PI3K and RAF effector arms in the IPC298 NRAS-mutant melanoma line for tumor growth.
###end p 37
###begin p 38
###xml 167 171 167 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61K</sup>
###xml 592 605 592 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g006">Figure 6A, 6B</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g007">7A</xref>
###xml 762 775 762 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g006">Figure 6A, 6B</xref>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g007">7A</xref>
###xml 785 793 785 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1051 1061 991 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g006">Figure. 6C</xref>
###xml 1066 1068 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g007">7B</xref>
###xml 1203 1213 1143 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g006">Figure. 6C</xref>
###xml 1218 1220 1158 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g007">7B</xref>
###xml 1226 1233 1166 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1401 1414 1341 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g006">Figure 6E, 6H</xref>
###xml 1419 1421 1359 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g007">7D</xref>
###xml 1600 1613 1540 1553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g006">Figure 6F, 6G</xref>
###xml 1618 1620 1558 1560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g007">7C</xref>
In order to understand if other NRAS mutant lines employ similar signaling cascades downstream of NRAS, we chose to study SK-MEL-30, another melanoma line with an NRASQ61K mutant allele. We generated SK-MEL-30 cells bearing inducible shRNA that target NRAS, BRAF, CRAF, PIK3CA alone, or combinations of BRAF and CRAF, or BRAF and PIK3CA. Inducible knock-down of NRAS, BRAF, CRAF individually or BRAF and CRAF or BRAF and PIK3CA together showed a decrease in the appropriate target protein with concomitant changes in downstream signaling as indicated by decreases in pERK and/or pAKT levels (Figure 6A, 6B, 7A). As with IPC298, knock-down of NRAS or the combined knock-down of BRAF and CRAF or BRAF and PI3KCA was effective in decreasing both the pERK and pAKT (Figure 6A, 6B, 7A). In in vitro proliferation studies, induction of shRNA targeting NRAS, BRAF, CRAF, dual targeting of BRAF/CRAF, or BRAF/PIK3CA had a reduction in proliferation of approximately20%, approximately12%, approximately20%, approximately40% and approximately28%, respectively (Figure. 6C and 7B), while the control shLUC or shRNAs targeting PIK3CA did not have a significant effect on proliferation compared to un-induced cells (Figure. 6C and 7B). In in vivo tumor growth studies, tumors carrying shRNAs that target NRAS alone, or combinations of BRAF and CRAF, or BRAF and PIK3CA, showed a significant delay in tumor growth (Figure 6E, 6H and 7D) compared to the corresponding sucrose controls. As observed in IPC298 cells, targeting BRAF, CRAF or PIK3CA individually in SK-MEL-30 cells did not effect in vivo tumor growth (Figure 6F, 6G and 7C). These results further confirm the requirement for sustained decrease in pERK and pAKT mediated signaling achieved either through combined targeting of BRAF and CRAF or BRAF and PIK3CA effector arms to be a more general requirement for effective therapy in NRAS mutant tumors.
###end p 38
###begin title 39
###xml 43 47 43 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61K</sup>
###xml 102 109 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Combined targeting of BRAF and CRAF in NRASQ61K-mutant SK-MEL-30 melanoma cell delays tumor formation in vivo.
###end title 39
###begin p 40
###xml 461 468 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
(A-B) Immunoblot analysis of SK-MEL-30 cells expressing control luciferase shRNA or shRNAs targeting NRAS, BRAF, CRAF or both BRAF and CRAF reveals respective protein knock-down and their effects on phosphorylation of downstream targets. (C) Proliferation of SK-MEL-30 cells expressing control luciferase shRNA or shRNAs targeting NRAS, BRAF, CRAF or both BRAF and CRAF. (D-H) shRNA targeting NRAS (E) or both BRAF and CRAF in SK-MEL-30 (H) delays tumor growth in vivo, whereas, induction of BRAF (F), CRAF (G) targeting shRNA or control luciferase (D) shRNA did not affect tumor growth. Each data point is the mean+/-SEM tumor volume of 10 mice. Dotted line in (D-H) represents data from dox treated animals.
###end p 40
###begin title 41
###xml 54 58 54 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61K</sup>
###xml 113 120 113 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Combined targeting of PIK3CA and BRAF together in NRASQ61K-mutant SK-MEL-30 melanoma cell delays tumor formation in vivo.
###end title 41
###begin p 42
###xml 404 411 404 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 550 554 <span type="species:ncbi:10090">mice</span>
(A) Immunoblot analysis of SK-MEL-30 cells expressing shRNAs targeting PIK3CA or both PIK3CA and BRAF reveal respective protein knock-down and their effects on phosphorylation of downstream targets. (B) Proliferation of SK-MEL-30 cells expressing control luciferase shRNA or shRNAs targeting PIK3CA or both PIK3CA and BRAF. (C-D) shRNA targeting both PIK3CA and BRAF in SK-MEL-30 (D) delays tumor growth in vivo, whereas, induction of PIK3CA (C) targeting shRNA alone did not affect tumor growth. Each data point is the mean+/-SEM tumor volume of 10 mice. Dotted line in (C-D) represents data from dox treated animals.
###end p 42
###begin title 43
RAS-effector targeting promotes cell cycle arrest
###end title 43
###begin p 44
###xml 476 483 452 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005717-t001">Table 1</xref>
###xml 488 496 464 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g008">Figure 8</xref>
###xml 660 667 636 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005717-t001">Table 1</xref>
###xml 672 680 648 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g008">Figure 8</xref>
To address the mechanism by which loss of RAS (KRAS in HCT116 and NRAS in IPC298) reduced cellular proliferation and delayed tumor growth, we analyzed cell cycle progression and apoptosis induction in these cells following dox treatment. Induction of NRAS shRNA expression in the NRAS mutant-IPC298 line led to approximately65% of the cells arresting in G1 compared to approximately47% of the cells in G1 in untreated cells. This led to a delayed entry into S and G2/M phase (Table 1 and Figure 8). In the KRAS mutant HCT116 cells, KRAS knock-down following KRAS shRNA induction, lead to the cells accumulating in S phase, thereby preventing G2/M progression (Table 1 and Figure 8).
###end p 44
###begin title 45
Targeting RAS and its downstream effectors leads to delay in cell cycle progression.
###end title 45
###begin p 46
###xml 323 330 323 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005717-t001">Table 1</xref>
A representative image showing the effect on cell cycle progression following knock-down of RAS and its downstream effectors as indicated in HCT116 or IPC298 cells. The complete results of cell cycle analysis from triplicates of two independent experiments along with the standard error of the mean values are presented in Table 1.
###end p 46
###begin title 47
Cell cycle status after RAS, RAF, PI3KCA and MEK knockdown.
###end title 47
###begin p 48
*p<0.05, **p<0.01 and ***p<0.001 with respect to no dox control of same cell cycle phase.
###end p 48
###begin p 49
###xml 359 366 359 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005717-t001">Table 1</xref>
###xml 371 379 371 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g008">Figure 8</xref>
###xml 676 684 676 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 710 717 710 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 735 743 735 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 762 769 762 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 882 889 882 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005717-t001">Table 1</xref>
###xml 894 902 894 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g008">Figure 8</xref>
###xml 1096 1103 1096 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Given that BRAF, CRAF, BRAF+CRAF and MEK1+2 double knock-down had an adverse effect on HCT116 cell proliferation and tumor growth, we examined the effect of targeting these genes on cell cycle progression. In all these knock-down cells, targeting the expression of these proteins led to an accumulation in G1 or S-phase, leading to delay in G2/M progression (Table 1 and Figure 8). These results suggest that targeting RAS and its downstream effector RAFs and the RAF-effectors MEK1+2 are mechanistically equivalent in KRAS mutant HCT116 cells. This is consistent with the fact that targeting RAS, BRAF, CRAF, BRAF+CRAF or MEK1+2 in HCT116 resulted in decreased proliferation in vitro and delayed tumor growth in vivo. Consistent with in vitro proliferation and in vivo tumor growth data, knock-down of BRAF, MEK1/2, and PIK3CA in IPC298 cells did not delay cell cycle progression (Table 1 and Figure 8). In contrast, knock-down of BRAF+CRAF, BRAF+PIK3CA, and MEK1/2+PIK3CA in IPC298 cells led to accumulation of cells in S or G1-phase consistent with the adverse effect on tumor growth observed in vivo.
###end p 49
###begin p 50
###xml 215 223 215 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005717-g002">Figure 2</xref>
To further dissect the mechanisms by which RAS targeting affects cell proliferation and delays tumor growth we tested the cells following RAS-targeting for apoptosis by annexin-V staining. As shown in Supplementary Figure 2, at the time-point observed, no increase in annexin-V staining was detected following RAS-knock-down in RAS-mutated IPC298 and HCT116 cells. However, BRAF knock-down in HCT116 showed a slight increase in annexin-V staining compared to the un-induced line, whereas all the other knock-down lines did not show an in increase in annexin-V staining following dox treatment. These data indicate that inhibition of cell proliferation and tumor growth upon RAS or a downstream RAS-effector knock-down is mainly due to delayed cell cycle progression.
###end p 50
###begin title 51
Discussion
###end title 51
###begin p 52
###xml 366 373 366 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 378 386 378 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 495 499 495 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G13D</sup>
###xml 568 572 568 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61L</sup>
###xml 609 613 609 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61K</sup>
###xml 694 702 694 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 707 714 707 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 748 755 748 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 878 886 878 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1013 1017 1013 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Lim1">[16]</xref>
###xml 1019 1023 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Shirasawa1">[31]</xref>
###xml 2096 2099 2096 2099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Samuels1">[9]</xref>
###xml 2130 2137 2130 2137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2336 2339 2336 2339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Samuels1">[9]</xref>
###xml 2578 2582 2578 2582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Ogino1">[32]</xref>
###xml 343 348 <span type="species:ncbi:9606">human</span>
###xml 934 943 <span type="species:ncbi:10090">nude mice</span>
###xml 2380 2388 <span type="species:ncbi:9606">patients</span>
###xml 2475 2483 <span type="species:ncbi:9606">patients</span>
Understanding the relative importance of oncogenic RAS effectors in tumor formation is fundamental to targeting RAS driven tumors using combinations of pharmacological inhibitors that are either available or in development. In this study we have addressed the relative importance of the RAS-effectors, RAF and PI3K, in a RAS mutant context in human tumor lines both in vivo and in vitro using a regulatable RNA interference system. We show that HCT116 colon tumor cells bearing an oncogenic KRASG13D mutation, IPC298 melanoma cells carrying an activated allele of NRASQ61L and SK-MEL-30 carrying a mutant NRASQ61K allele are dependent on the RAS pathway for their growth and proliferation both in vitro and in vivo. Knock-down of these RAS alleles in vivo leads to a significant delay in tumor growth and is consistent with the cell cycle arrest observed in the knock-down line in vitro. This is in agreement with a previous study in nude mice that demonstrated the requirement of mutant RAS for tumor formation, [16], [31]. To address the relevance of the effector arms of RAS in tumor maintenance and growth, we targeted the major RAS effectors RAF and PI3K using an inducible shRNA system. In HCT116, a colon cancer line, that carries a mutant KRAS allele, we find that interfering with the RAF effector axis at the level of RAF (BRAF and CRAF) and MEK (MEK1 and MEK2) was effective in delaying tumor growth. In contrast, there was no effect on tumor growth and maintenance when PIK3CA alone was knocked down, despite the fact that PIK3CA is mutated in this line. It is possible that in HCT116 cells, RAS could engage other PI3K family members to promote tumor growth. This is unlikely as pAKT levels are reduced following PIK3CA knock-down indicating that PIK3CA is the major PI3K isoform engaged by RAS in these cells. Further, this data suggest that the RAF-MEK-ERK cascade is predominantly engaged by KRAS in these cancer cells for growth and proliferation. In HCT116 cells, knock-in mutations that revert the mutant PIK3CA to WT affects it ability to proliferate, migrate and metastasize [9]. However, consistent with our in vivo data an HCT116 PIK3CA wild type line generated by knocking-in a copy of the WT PIK3CA in place of the mutant PIK3CA, did not block the knock-in revertant line's ability to form sub-cutaneous tumors [9]. Also, recently a study of colon cancer patients showed that PIK3CA mutations did not confer any significant effect on mortality among patients with KRAS-mutated tumors and is consistent with our findings on tumors growth in HCT116 cells [32]. These data taken together with our findings suggest that, in the colon cancer line, KRAS predominantly engages the RAF-MEK-ERK effector arm. This is in contrast to studies in other tumor types where the PIK3CA pathway is shown to be sufficient for tumor initiation and maintenance.
###end p 52
###begin p 53
###xml 621 625 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Menges1">[33]</xref>
###xml 1108 1112 1108 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Montagut1">[34]</xref>
###xml 1114 1118 1114 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Smalley2">[35]</xref>
Our data shows that effective targeting of mutant NRAS driven tumor requires sustained reduction in pAKT and pERK. This can be achieved either by combined targeting of BRAF and CRAF, PIK3CA and BRAF or PIK3CA and MEK1+2. However, inhibition of MEK1+2 alone in the NRAS mutant line was not equivalent to inhibiting BRAF and CRAF together, as assessed by pERK and pAKT, suggesting the presence of differential signaling and feedback effects that arise from perturbing different nodes along the RAS/RAF signaling cascade. This is consistent with previously reported feedback and cross talk between the RAF and PI3K pathways [33]. These results have implications for therapeutic targeting of NRAS mutant melanomas where a dual BRAF/CRAF inhibitor or a BRAF and a PIK3CA inhibitor or a MEK and a PIK3CA inhibitor in combination is likely to show efficacy in the clinic. It is interesting to note that several studies also suggest the relevance of combined inhibition of CRAF and BRAF in a BRAF mutant context for efficacy and may prove to be relevant strategy for treatment of both NRAS and BRAF mutant melanomas [34], [35].
###end p 53
###begin p 54
###xml 706 713 <span type="species:ncbi:9606">patient</span>
Our data suggests that the pathways engaged by mutant RAS that promote tumor formation show differences that are possibly inherent to each tissue or tumor type. Further investigation of the RAS-effector arms engaged within each tumor type may reveal differences that correlate with known tumor subtypes or form the basis for a better molecular classification of tumor subtypes. In the clinical context, understanding the specific effector arms engaged by RAS in driving tumorigenesis is critical to successfully treating these cancers. Developing gene signatures that allow identification and classification of tumors into RAS effector classes, based on effectors engaged by RAS, should allow for rational patient therapies that utilize appropriate pharmacological inhibitors either alone or in combination.
###end p 54
###begin title 55
Materials and Methods
###end title 55
###begin title 56
Cell lines and antibodies
###end title 56
###begin p 57
###xml 340 348 340 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005717.s003">Table-S1</xref>
###xml 716 727 <span type="species:ncbi:3704">horseradish</span>
Colon cancer cell line HCT116 was purchased from ATCC (American Type Culture Collection, Manassas, VA). IPC-298, a cutaneous melanoma line and SK-MEL-30, a melanoma line, were obtained from German Collection of Microorganisms and Cell Cultures (DMZ, Braunschweig, Germany). Mutation status of the cell lines used in this study is listed in Table-S1. Antibodies used in the study are as follows: CRAF, pAKT, AKT, ERK2, p-ERK1/2 (Thr202/Tyr204), MEK1, MEK2 and p-MEK1/MEK2 (Ser217/221) (Cell Signaling Technology, Beverly, MA); BRAF and NRAS (F-7; Santa Cruz Biotechnology, Santa Cruz, CA); KRAS (Novus Biologicals, Littleton, CO), PIK3CA (Millipore, Temecula, CA), beta-actin (Sigma Life Science, St. Louis, MO); and horseradish peroxidase (HRP)-conjugated secondary antibodies (Pierce Biotechnology, Rockford, IL).
###end p 57
###begin title 58
Generation of inducible-shRNA cell pools
###end title 58
###begin p 59
###xml 62 70 62 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005717.s004">Table-S2</xref>
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Gray1">[29]</xref>
###xml 195 199 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Hoeflich1">[30]</xref>
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Gray1">[29]</xref>
###xml 301 305 301 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Hoeflich1">[30]</xref>
###xml 812 816 812 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Gray1">[29]</xref>
###xml 818 822 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005717-Hoeflich1">[30]</xref>
###xml 429 455 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 490 495 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Hairpin oligonucleotides used in this study are listed in the Table-S2. They were based on a collection of siRNAs from Dharmacon Inc., (Chicago, IL) or based on previously published shRNAs [29], [30]. Inducible-shRNA bearing lentivirus constructs were made based on previously described methods [29], [30] by co-transfecting pHUSH-Lenti-GFP or pHUSH-Lenti-dsRed constructs containing a desired shRNA with plasmids expressing the vesicular stomatitis virus (VSV-G) envelope glycoprotein and HIV-1 packaging proteins (GAG-POL) in HEK293T cells using Lipofectamine (Invitrogen, Carlsbad, CA). Target cells were transduced with these viruses and sterile sorted (top 10%) by flow cytometry for presence of dsRed or GFP or both. Cells were characterized for knock-down by western blot analysis as previously described [29], [30].
###end p 59
###begin title 60
Anchorage independent growth assay
###end title 60
###begin p 61
Twenty thousand cells in media containing 0.35% agarose with or without 1.0 microg/ml dox was plated on a layer of 0.5% agar in 10% serum. After a 2-week incubation at 37degreesC colonies were stained with 1 microM Calcein-AM, imaged using ImageXpress Micro (Molecular Devices, Sunnyvale, CA) and processed using MetaXpress Version 2.0 (Molecular Devices, Sunnyvale, CA) software to obtain colony counts.
###end p 61
###begin title 62
Xenograft studies
###end title 62
###begin p 63
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nu/nu</italic>
###xml 164 165 164 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 348 349 344 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 731 732 727 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 283 292 <span type="species:ncbi:10090">nude mice</span>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
###xml 659 663 <span type="species:ncbi:10090">mice</span>
###xml 691 695 <span type="species:ncbi:10090">Mice</span>
###xml 767 771 <span type="species:ncbi:10090">mice</span>
Six- to eight-week-old female athymic nu/nu mice were obtained from Charles River Laboratories (Wilmington, MA). For xenograft studies following trypsinization 5x106 HCT116 cells or 1x107 IPC298 or SK-MEL-30 were resuspended in 200 microl of PBS and injected into the right flank of nude mice. Once the tumors reached a mean volume of 150 to 200 mm3, the mice with similarly sized tumors were grouped and put on either 5% sucrose solution containing 1 mg/mL dox, for the treatment arm, or 5% sucrose only for the animals in control arm. Dox treatment induces the relevant shRNA. Tumor growth was monitored twice weekly for 4-8 weeks using calipers. Also, the mice were weighed twice a week. Mice whose tumor burden reached 2,000 mm3 were euthanized. Between 8 and 10 mice were used for each treatment group and results are presented as mean tumor volume+/-SEM.
###end p 63
###begin title 64
Cell Proliferation
###end title 64
###begin p 65
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
In order to assess proliferation, 1x104 cells/well in 100 microl volume was plated in a 96-well plate. Cells were treated with 1 microg/ml dox and proliferation was assessed after 4 days using Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega Corporation, Madison, WI). A standard curve of luminescence as a function of cell number was used to calculate the number of cells in each treatment. Data are presented as mean+/-SEM from at least three replicate experiments.
###end p 65
###begin title 66
Cell cycle analysis
###end title 66
###begin p 67
Cells were seeded in 6 well plates and treated with 1 microg/ml dox. After 72 h, cells were fixed in 70% ethanol for 1 hr at 4degreesC and stained with propidium iodide (PI) staining solution (50 microg/ml PI and 500 microg/ml DNase free RNase in PBS) and analyzed by flow cytometry (BD FACScan) using the CellQuest program. The data were analyzed using Mod Fit LT 3.0 cell cycle analysis software.
###end p 67
###begin title 68
Apoptosis assay
###end title 68
###begin p 69
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
We used annexin V to measure the levels of apoptosis. Briefly, 4x105 cells, RAS, BRAF and MEK1+2 shRNA containing HCT116 or IPC298 stable cells, were plated in 6-well plates and treated with dox (1 microg/ml for 72 hrs) in triplicate before staining with annexin V. After treatment cells were harvested, washed once with PBS, stained with FITC-conjugated anti-annexin V antibody and 100 microg/ml of propidium iodide in binding buffer for 15 min at room temperature. The cells were then analyzed with a flow cytometer (BD FACSCalibur). Background green fluorescence intensity due to presence of MEK1-shRNA-GFP in MEK1+2 cells were subtracted out before the calculating the fraction of annexin-V positive cells in case of MEK1+2 cells.
###end p 69
###begin title 70
Statistical Analysis
###end title 70
###begin p 71
Student's t-test (two-tailed) was used for statistical analyses to compare treatment groups using GraphPad Prism 5.00 (GraphPad Software, San Diego, CA). A P-value <0.05 was considered statistically significant (*p<0.05, **p<0.01 and ***p<0.001).
###end p 71
###begin title 72
Supporting Information
###end title 72
###begin p 73
###xml 90 94 <span type="species:ncbi:10090">mice</span>
MEK inhibitor is effective in KRAS mutant HCT116 cells. Treatment of HCT116 tumor-bearing mice with small molecule MEK inhibitor resulted in significant inhibition of tumor growth (p<0.001). Doses were well tolerated as determined by the change in animal weight (data not shown). MEK small molecule inhibitor was administered daily by oral gavage at a final concentration of 6 mg/kg. The compound was prepared fresh weekly in 0.5% methylcellulose and 0.2% Tween 80 in water and stored at 4degreesC. Tumor growth was monitored twice weekly for 4-8 weeks using calipers.
###end p 73
###begin p 74
(0.02 MB TIF)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
Induction of apoptosis measured by Annexin-V staining, in RAS mutant lines following induction of shRNA. Apoptosis in HCT116 or IPC298 lines expressing shRNAs that target KRAS or NRAS (A), BRAF (B) and both MEK1 and MEK2 (C). Results shown are mean+/-SEM of experiments from triplicates of two independent experiments. *P<0.001 vs untreated cells.
###end p 76
###begin p 77
(0.14 MB TIF)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin p 79
(0.04 MB TIF)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin p 81
(0.21 MB TIF)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
We thank Laurie Gilmour, Dragan Sebisanovic, Christine Orr, Tom Truong, Klara Totpal, Michelle Nannini, Priscilla Mantik, Chaitali Parikh and members of the FACS and Sequencing labs for their help.
###end p 83
###begin title 84
References
###end title 84
###begin article-title 85
Hyperactive Ras in developmental disorders and cancer.
###end article-title 85
###begin article-title 86
Targeting oncogenic Ras.
###end article-title 86
###begin article-title 87
Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders.
###end article-title 87
###begin article-title 88
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
###end article-title 88
###begin article-title 89
Tumour cell survival signalling by the ERK1/2 pathway.
###end article-title 89
###begin article-title 90
Oncogenic PI3K deregulates transcription and translation.
###end article-title 90
###begin article-title 91
New insight into BRAF mutations in cancer.
###end article-title 91
###begin article-title 92
Pten, tumorigenesis, and stem cell self-renewal.
###end article-title 92
###begin article-title 93
###xml 51 56 <span type="species:ncbi:9606">human</span>
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
###end article-title 93
###begin article-title 94
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
###end article-title 94
###begin article-title 95
Helical domain and kinase domain mutations in p110{alpha} of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
###end article-title 95
###begin article-title 96
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
###end article-title 96
###begin article-title 97
The prevalence of PIK3CA mutations in gastric and colon cancer.
###end article-title 97
###begin article-title 98
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.
###end article-title 98
###begin article-title 99
###xml 7 12 <span type="species:ncbi:9606">human</span>
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
###end article-title 99
###begin article-title 100
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.
###end article-title 100
###begin article-title 101
Raf kinases: oncogenesis and drug discovery.
###end article-title 101
###begin article-title 102
The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
###end article-title 102
###begin article-title 103
Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy.
###end article-title 103
###begin article-title 104
Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
###end article-title 104
###begin article-title 105
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
###end article-title 105
###begin article-title 106
###xml 235 239 <span type="species:ncbi:10090">mice</span>
Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice.
###end article-title 106
###begin article-title 107
###xml 179 184 <span type="species:ncbi:10090">mouse</span>
Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model.
###end article-title 107
###begin article-title 108
Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy.
###end article-title 108
###begin article-title 109
###xml 85 91 <span type="species:ncbi:10090">murine</span>
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
###end article-title 109
###begin article-title 110
###xml 66 71 <span type="species:ncbi:9606">human</span>
K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
###end article-title 110
###begin article-title 111
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.
###end article-title 111
###begin article-title 112
Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.
###end article-title 112
###begin article-title 113
pHUSH: a single vector system for conditional gene expression.
###end article-title 113
###begin article-title 114
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.
###end article-title 114
###begin article-title 115
###xml 18 23 <span type="species:ncbi:9606">human</span>
Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.
###end article-title 115
###begin article-title 116
###xml 56 64 <span type="species:ncbi:9606">patients</span>
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
###end article-title 116
###begin article-title 117
Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor.
###end article-title 117
###begin article-title 118
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
###end article-title 118
###begin article-title 119
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
###end article-title 119
###begin p 120
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: All authors are employees of Genentech Inc. No outside funding was received for performing this research work.
###end p 120
###begin p 121
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: That authors have no support or funding to report.
###end p 121

